# A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL

Source: https://onco.cc/trials/nct04496349/  
OnCo record `nct04496349` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of APG-115 in hodgkin lymphoma, run by Ascentage Pharma Group Inc., now recruiting.

## Summary

A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL is a phase 2 interventional study registered as NCT04496349 by Ascentage Pharma Group Inc., with 78 participants planned, started 2021-07-12 and due to reach its primary completion in 2026-05-31. Interventions recorded: APG-115 and APG-2575.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04496349
- Phase: 2
- Setting: A Phase IIa Study Evaluating the Pharmacokinetics, Safety and Efficacy of APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With Relapsed/Refractory T-Cell Prolymphocytic Leukemia (R/R T-PLL) or Non-Hodgkin's Lymphoma (NHL).
- Sponsor: Ascentage Pharma Group Inc.
- Enrolled: 78

## Sources

- ClinicalTrials.gov NCT04496349: https://clinicaltrials.gov/study/NCT04496349

## Connected records

- cancers: [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/)
- companies: [Ascentage Pharma](https://onco.cc/companies/ascentage-pharma/)

---
JSON: https://onco.cc/api/v1/entities/nct04496349.json